Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen.
Kong A, Rea D, Ahmed S, Beck JT, López López R, Biganzoli L, Armstrong AC, Aglietta M, Alba E, Campone M, Hsu Schmitz SF, Lefebvre C, Akimov M, Lee SC. Kong A, et al. Among authors: aglietta m. Oncotarget. 2016 Jun 21;7(25):37680-37692. doi: 10.18632/oncotarget.8974. Oncotarget. 2016. PMID: 27129177 Free PMC article. Clinical Trial.
Trastuzumab-based combination therapy for breast cancer.
Montemurro F, Valabrega G, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Expert Opin Pharmacother. 2004 Jan;5(1):81-96. doi: 10.1517/14656566.5.1.81. Expert Opin Pharmacother. 2004. PMID: 14680438 Review.
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F, Redana S, Viale G, Sanna G, Donadio M, Valabrega G, del Curto B, Bottini A, Botti G, dei Tos AP, Jacomuzzi ME, Di Bonito M, Danese S, Clavarezza M, Kulka J, Di Palma S, Durando A, Sapino A, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Clin Breast Cancer. 2008 Oct;8(5):436-42. doi: 10.3816/CBC.2008.n.053. Clin Breast Cancer. 2008. PMID: 18952558
Duration of trastuzumab for HER2-positive breast cancer.
Montemurro F, Aglietta M. Montemurro F, et al. Among authors: aglietta m. Lancet Oncol. 2013 Jul;14(8):678-9. doi: 10.1016/S1470-2045(13)70273-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764182 No abstract available.
469 results